Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKM regimen in metastatic colorectal cancer to the liver
NCT03403634Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Apr 2018
- Primary completion
- Dec 2020
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of celecoxib oral solution, interferon alfa-2b and rintatolimod in colorectal cancer (CRC), sponsored by Roswell Park Comprehensive Cancer Center. Started Apr 2018; status: completed.
02
Drugs
celecoxib oral solutioninterferon alfa-2brintatolimod
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03403634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03403634.